Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

[1]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[2]  H. Hurwitz,et al.  Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  P. LoRusso,et al.  Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors. , 2015 .

[4]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[5]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[6]  David C. Smith,et al.  Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors. , 2014 .

[7]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[8]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[9]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[10]  Laura A. Sullivan,et al.  The VEGF family in cancer and antibody-based strategies for their inhibition , 2010, mAbs.

[11]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Desai,et al.  Human liver microsomal metabolism of paclitaxel and drug interactions , 1998, European Journal of Drug Metabolism and Pharmacokinetics.

[13]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[14]  R. Herbst.  Toxicities of antiangiogenic therapy in non-small-cell lung cancer. , 2006, Clinical lung cancer.

[15]  T. Yoshino,et al.  Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer , 2006, Gastric Cancer.

[16]  N. Hanna,et al.  Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Gelmon,et al.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Verweij,et al.  Distribution of paclitaxel in plasma and cerebrospinal fluid , 2003, Anti-Cancer Drugs.

[19]  Y. Mok,et al.  Paclitaxel, 5‐fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma , 1999, Cancer.

[20]  N. Saijo,et al.  Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities , 1995, Japanese journal of cancer research : Gann.

[21]  L. Norton,et al.  Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity , 1994, International journal of clinical & laboratory research.